Related Experiment Videos
Death from drug-induced hemolytic anemia
R Taraszewski1, R Harvey, P Rosman
1Department of Internal Medicine, Western Reserve Care System-Southside Medical Center, Youngstown, OH 44501.
Postgraduate Medicine
|May 15, 1989
Summary
Trimethoprim-sulfamethoxazole can cause fatal hemolytic anemia, even at low doses. This drug combination affects folic acid metabolism, leading to severe hematologic reactions.
Area of Science:
- Pharmacology
- Hematology
- Toxicology
Background:
- Trimethoprim-sulfamethoxazole is a commonly prescribed antibiotic.
- Hematologic reactions are known adverse effects of this drug combination.
- Folic acid metabolism interference is a proposed mechanism for these reactions.
Observation:
- A 71-year-old male developed fatal hemolytic anemia after receiving trimethoprim-sulfamethoxazole for presumed cystitis.
- The patient's reaction occurred despite potentially low-dose or short-term therapy.
Findings:
- Trimethoprim-sulfamethoxazole can induce severe hematologic complications, including megaloblastic anemia, neutropenia, and acute hemolytic anemia.
- Sulfamethoxazole alone can cause acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase deficiency.
- Acute hematologic reactions may occur even with lower doses or shorter durations of therapy than typically associated with such complications.
Implications:
- Clinicians should be aware of the potential for severe, acute hematologic reactions to trimethoprim-sulfamethoxazole, irrespective of dose or duration.
- Careful patient monitoring is crucial, especially in individuals with pre-existing risk factors for hematologic disorders.
- Further research may be warranted to elucidate the precise mechanisms and identify patients at highest risk for these adverse events.